氧嗪酸钾(Oteracil Potassium) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所）

在研机构-

非在研机构

山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所）

最高研发阶段无进展临床申请

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

结构

分子式C4H3KN3O4

InChIKeyIXGSVCGUTCBYTE-UHFFFAOYSA-N

CAS号2207-75-2

关联

6

项与氧嗪酸钾相关的临床试验

ChiCTR1900027160 / Recruiting早期临床1期

A single-arm, observational, single-center, open label study for Toripalimab with or without Paclitaxel (albumin bound) plus Tegafur, Gimeracil and Oteracil Potassium Capsules as a Neoadjuvant therapy for esophageal cancer before operation

开始日期2019-11-01

申办/合作机构

中国人民解放军总医院

ChiCTR1900022946 / Suspended临床2期IIT

A phase II study for Tegafur, Gimeracil and Oteracil potassium with or without Thalidomide for heavily treated colorectal cancer patients

开始日期2019-05-18

申办/合作机构-

ChiCTR-ONC-11001804 / Completed临床2期IIT

Efficacy and Toxicity of Docetaxel with Cisplatin and Oteracil Potassium (S-1) for Advanced Gastric Cancer

开始日期2007-02-03

申办/合作机构-

100 项与氧嗪酸钾相关的临床结果

登录后查看更多信息

100 项与氧嗪酸钾相关的转化医学

登录后查看更多信息

100 项与氧嗪酸钾相关的专利（医药）

登录后查看更多信息

258

项与氧嗪酸钾相关的文献（医药）

2024-03-01·Respirology Case Reports

BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report

作者: Urabe, Naohisa ; Isobe, Kazutoshi ; Sekiya, Muneyuki ; Sadamoto, Sota ; Shimizu, Hiroshige ; Miyoshi, Shion ; Motohashi, Takumi ; Usui, Yusuke ; Kishi, Kazuma ; Yoshizawa, Takahiro ; Homma, Sakae ; Tochigi, Naobumi ; Sakamoto, Susumu ; Nakamura, Yasuhiko

AbstractA 66‐year‐old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First‐line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second‐line pemetrexed treatment, followed by third‐line nivolumab, fourth‐line docetaxel and bevacizumab, fifth‐line tegafur‐gimeracil‐oteracil, and sixth‐line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography‐guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne® CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years.

2024-01-07·Japanese Journal of Clinical Oncology

Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04)

Article

作者: Imamura, Yoshinori ; Mase, Takahiro ; Shimoyama, Rai ; Sawamukai, Keiji ; Tanaka, Satomi ; Taguri, Masataka ; Minami, Hironobu ; Hayashi, Maki ; Uryu, Kiyoaki ; Okuda, Tadahisa ; Fujimura, Yoshiaki

AbstractObjectivesTo investigate temporal trends in treatment patterns and prognostic factors for overall survival in patients with metastatic biliary tract cancer.MethodsFrom the Tokushukai REAl-world Data project, we identified 945 patients with metastatic biliary tract cancer treated with gemcitabine, tegafur/gimeracil/oteracil, gemcitabine plus cisplatin, gemcitabine plus tegafur/gimeracil/oteracil or gemcitabine plus cisplatin and tegafur/gimeracil/oteracil between April 2010 and March 2022. Stratified/conventional Cox regression analyses were conducted to examine the association between overall survival and patient- and tumour-related factors, study period, hospital volume, hospital type and first-line chemotherapy regimen. Using inverse probability of treatment weighting with propensity scores, overall survival was also compared between monotherapy and combination therapy groups.ResultsWe enrolled 366 patients (199 men; median age, 72 years). Over a median follow-up of 5.2 months, the median overall survival was 7.0 months (95% confidence interval 6.2–9.0), and the median time to treatment failure was 3.5 months (95% confidence interval 3.1–4.5). Median overall survival and time to treatment failure for gemcitabine/tegafur–gimeracil–oteracil/gemcitabine plus cisplatin/gemcitabine plus tegafur–gimeracil–oteracil/gemcitabine plus cisplatin and tegafur–gimeracil–oteracil regimen were 6.2/6.6/7.9/16.2/15.1 and 2.8/3.4/4.1/15.3/7.4 months, respectively. Primary disease site, previous surgery, previous endoscopic procedures and hospital type were identified as significant prognostic factors. Inverse probability of treatment weighting analysis demonstrated that combination therapy had a significantly better prognosis than monotherapy (hazard ratio 0.61, 95% confidence interval 0.43–0.88, P = 0.006).ConclusionsOur real-world data analysis showed that standard care for metastatic biliary tract cancer is widely used in hospitals throughout Japan and verified the survival benefits of combination therapy over monotherapy observed in prior clinical trials.Clinical trial numberUMIN000050590 (http://www.umin.ac.jp/ctr/index.htm).

2024-01-01·Integrative Cancer Therapies

Effects of Traditional Chinese Medicine “Fuzheng Qingdu Decoction” on Autonomic Function and Cancer-Related Symptoms in Patients with Advanced Gastric Cancer undergoing Chemotherapy: A Controlled Trial

Article

作者: Wang, Zaichuan ; Zhang, Xiaochun ; Yuan, Chengjia ; Tian, Cuiling ; Wu, Shuang ; Wu, Yang

Objective: To evaluate the effects of Fuzheng Qingdu Decoction (FZQDD) on the autonomic function and cancer-related symptoms of patients with advanced gastric cancer undergoing chemotherapy to verify its clinical efficacy. Methods: Sixty-two patients with stage III or IV gastric cancer were included in this study. The patients were divided into 2 groups: the chemotherapy (33 patients) and chemotherapy with FZQDD (29 patients) groups. The primary outcome was the autonomic function of the patients before and after the interventions. The parameters that were used to assess autonomic function were deceleration capacity (DC) and acceleration capacity (AC) of heart rate and heart rate variability (HRV), which comprised standard deviation of the normal-normal interval (SDNN), root mean square of successive interval differences (RMSSD), low-frequency power (LF), high-frequency power (HF), total power (TP), and LF–HF ratio. The secondary outcomes were cancer-related symptoms and the quality of life. Results: DC and HRV parameters (ie, SDNN, RMSSD, LF, HF, and TP) were significantly decreased in the chemotherapy group; however, AC significantly increased after the interventions. No significant differences were observed in the DC, AC, and HRV parameters before and after the interventions in the chemotherapy with FZQDD group. Nevertheless, the changes in DC, AC, and HRV parameters (SDNN, RMSSD, HF, and TP) before and after the interventions were statistically significant between both the groups. FZQDD significantly improved the cancer-related symptoms and the quality of life of the patients. Conclusions: Oxaliplatin combined with S-1 (tegafur, gimeracil, and oteracil potassium) can impair autonomic modulation in patients with advanced gastric cancer. FZQDD can alleviate autonomic dysfunction by increasing the parasympathetic activity and decreasing the sympathetic tone, helping patients restore the dynamic sympathovagal balance, and significantly improving the cancer-related symptoms and the quality of life of patients.

100 项与氧嗪酸钾相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02645864 (Pubmed \| Aging (Albany NY)) 人工标引	临床1期	食管鳞状细胞癌二线	39	Tegafur+Gimeracil+Oteracil+Capecitabine+Apatinib	(築簾鏇蓋窪獵廠觸構鏇) = 衊構築齋鑰獵鑰窪壓鹽觸淵鏇積膚網製鬱窪繭 (鑰積膚構鏇醖鹽醖艱築, 14.9 ~ 40.1) 更多	积极	2021-03-10